BioCentury
ARTICLE | Politics, Policy & Law

The Counterattack

September 28, 2009 7:00 AM UTC

Even though the Senate Finance Committee will continue debating amendments to its healthcare reform legislation this week, much of the focus for pharmaceutical and biotech companies has already shifted to the next legislative inflection points on the Senate floor.

In the course of four days of heated debate last week, the America's Healthy Future Act authored by Senate Finance Committee chairman Max Baucus (D-Mont.) emerged with only minor changes to a bill that rewards the Pharmaceutical Research and Manufacturers of America for its early support...